Overview

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

Status:
RECRUITING

Trial end date:
2026-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity of lung infections in patients with hematologic malignancies and recipients of hematopoietic stem cell transplantation with documented viral infections due to PIV, hMPV, or RSV. PUL-042 or a placebo will be administered 3 times over a 6-day period. The total duration of the study will be approximately 30 days.

Phase:

PHASE2

Details

Lead Sponsor:

Pulmotect, Inc.

Collaborator:

Cancer Prevention Research Institute of Texas

Treatments:

Pam2CSK4 acetate and ODN M362 combination